Stocks
Eli Lilly and Company Financial Statements (LLY) |
||||||||||
| Eli Lilly and Companysmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 27.04.2023 | 08.08.2023 | 02.11.2023 | 21.02.2024 | 30.04.2024 | 30.04.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 6 960 | 8 312 | 9 499 | 9 353 | 8 768 | 35 932 | |||
| Operating Income, bln rub | 1 494 | 2 126 | 450.4 | 3 078 | 2 620 | 8 274 | ||||
| EBITDA, bln rub | ? | 1 704 | 2 320 | 6 401 | 3 604 | 3 211 | 15 535 | |||
| Net profit, bln rub | ? | 1 345 | 1 763 | -57.4 | 2 190 | 2 243 | 6 138 | |||
| OCF, bln rub | ? | 1 731 | 631.9 | 2 190 | -311.9 | 1 166 | 3 676 | |||
| CAPEX, bln rub | ? | 903.5 | 836.3 | 4 001 | 1 651 | 986.3 | 7 475 | |||
| FCF, bln rub | ? | 827.1 | -204.4 | -1 812 | -1 963 | 179.7 | -3 799 | |||
| Dividend payout, bln rub | 1 017 | 1 018 | 1 016 | 1 018 | 1 169 | 4 221 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 75.6% | 57.7% | 0.00% | 46.5% | 52.1% | 68.8% | ||||
| OPEX, bln rub | 3 734 | 4 282 | 4 213 | 4 616 | 4 614 | 17 725 | ||||
| Cost of production, bln rub | 1 627 | 1 807 | 1 860 | 1 659 | 1 534 | 6 861 | ||||
| R&D, bln rub | 1 985 | 2 357 | 2 409 | 2 563 | 2 523 | 9 851 | ||||
| Interest expenses, bln rub | 102.8 | 120.3 | 124.6 | 93.7 | 133.8 | 472.4 | ||||
| Assets, bln rub | 53 163 | 54 814 | 57 916 | 64 006 | 63 944 | 63 944 | ||||
| Net Assets, bln rub | ? | 11 190 | 11 064 | 11 220 | 10 772 | 12 812 | 12 812 | |||
| Debt, bln rub | 18 884 | 18 820 | 20 168 | 25 225 | 26 211 | 26 211 | ||||
| Cash, bln rub | 3 669 | 2 829 | 2 494 | 2 928 | 2 586 | 2 586 | ||||
| Net debt, bln rub | 15 214 | 15 991 | 17 674 | 22 298 | 23 625 | 23 625 | ||||
| Ordinary share price, rub | 343.4 | 469.0 | 537.1 | 582.9 | 778.0 | 579.6 | ||||
| Number of ordinary shares, mln | 901.0 | 899.7 | 899.8 | 949.4 | 900.8 | 900.8 | ||||
| Market cap, bln rub | 309 421 | 421 941 | 483 310 | 553 412 | 700 786 | 522 104 | ||||
| EV, bln rub | ? | 324 636 | 437 932 | 500 984 | 575 710 | 724 411 | 545 729 | |||
| Book value, bln rub | 30 | 81 | 354 | -1 074 | 1 110 | 1 110 | ||||
| EPS, rub | ? | 1.49 | 1.96 | -0.06 | 2.31 | 2.49 | 6.81 | |||
| FCF/share, rub | 0.92 | -0.23 | -2.01 | -2.07 | 0.20 | -4.22 | ||||
| BV/share, rub | 0.03 | 0.09 | 0.39 | -1.13 | 1.23 | 1.23 | ||||
| EBITDA margin, % | ? | 24.5% | 27.9% | 67.4% | 38.5% | 36.6% | 43.2% | |||
| Net margin, % | ? | 19.3% | 21.2% | -0.60% | 23.4% | 25.6% | 17.1% | |||
| FCF yield, % | ? | 1.22% | 0.76% | -0.03% | -0.57% | -0.54% | -0.73% | |||
| ROE, % | ? | 50.8% | 58.7% | 44.5% | 48.6% | 47.9% | 47.9% | |||
| ROA, % | ? | 10.7% | 11.9% | 8.61% | 8.19% | 9.60% | 9.60% | |||
| P/E | ? | 54.4 | 64.9 | 96.9 | 105.6 | 114.2 | 85.1 | |||
| P/FCF | 81.7 | 131.4 | -2 931 | -175.6 | -184.4 | -137.4 | ||||
| P/S | ? | 11.2 | 14.3 | 15.1 | 16.2 | 19.5 | 14.5 | |||
| P/BV | ? | 10 246 | 5 184 | 1 367 | -515.1 | 631.1 | 470.2 | |||
| EV/EBITDA | ? | 37.8 | 49.7 | 39.1 | 41.0 | 46.6 | 35.1 | |||
| Debt/EBITDA | 1.77 | 1.81 | 1.38 | 1.59 | 1.52 | 1.52 | ||||
| R&D/CAPEX, % | 219.7% | 281.8% | 60.2% | 155.2% | 255.8% | 131.8% | ||||
| CAPEX/Revenue, % | 13.0% | 10.1% | 42.1% | 17.7% | 11.2% | 20.8% | ||||
| Eli Lilly and Company shareholders | ||||||||||
